| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2023-02-19 |
| タイトル |
|
|
タイトル |
Novel extrapancreatic effects of incretin |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Gastric inhibitory polypeptide |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Glucagon-like peptide-1 |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Incretin |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
Yamada, Yuichiro
Tsukiyama, Katsushi
Sato, Takehiro
Shimizu, Tatsunori
Fujita, Hiroki
Narita, Takuma
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
The hormonal factors implicated as transmitters of signals from the gut to pancreatic -cells are referred to as incretins. Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are incretins. In addition to the insulinotropic effects, we have shown, using the GIP receptor and GLP-1 receptor-deficient mice, that GIP and GLP-1 have direct actions on adipocytes and the kidney, respectively. Because GIP receptors and GLP-1 receptors are differentially expressed in a tissue-specific manner, GIP and GLP-1 have specific physiological activities, and further comprehensive characterization of the extrapancreatic actions of GIP and GLP-1 is anticipated, as dipeptidyl peptidaseIV inhibitors activate both GIP and GLP-1 signaling. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
en : Journal of Diabetes Investigation
巻 7,
号 S1,
p. 76-79,
発行日 2016
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2040-1116 |
| 出版者 |
|
|
出版者 |
John Wiley and Sons Inc |
| 関連情報 |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/jdi.12495 |
| 権利情報 |
|
|
権利情報 |
©2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, LtdThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distributionin any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
iA_2022_56.pdf (342.7 kB)
